Global Clinical Trials, a global mid-sized contract research organization (CRO) is proud to announce it will manage and further support the clinical development of a Phase III multicenter clinical trial in chronic idiopathic (immune) thrombocytopenic purpura with patients aged from 18 to 65 years old inclusive amongst 20 sites.

It is a randomized, international, multicenter single-blind study to compare the efficacy and safety of the drug for solution for subcutaneous injection 250 µg versus comparator drug in patients with chronic idiopathic (immune) thrombocytopenic purpura. All patients will be administered a therapy: a parenteral therapy with the test drug product/reference drug product with weekly injections for 12 weeks.

GCT has already started early project set-up activities and will integrate and harmonize the cooperation of all involved parties on this project.

Dr. Eugene Selivra, GCT CEO commented, “The positive outcome of this development program could provide an effective medication for the treatment of severe cases of immune thrombocytopenic purpura, saving lives worldwide. Our team is working hard on this project and hopes that these efforts will contribute to new scientific knowledge, which will make treatment more effective and improve the quality of life of patients.”